Langhorne
Langhorne
Langhorne, Pennsylvania, United States25 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal adenocarcinoma, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT07392892 | |
| Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, invasive breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-10-02 | NCT02445391 | |
| Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, metastatic melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2026-10-01 | NCT01134614 | |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | breast adenocarcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00433511 | |
| Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00310180 | |
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 3 | 2026-09-30 | NCT05611931 | |
| MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study | bone disorder, lumbar spinal stenosis, musculoskeletal system disorder, spinal stenosis, vertebral column disorder | Recruiting | Not stated | 2026-09-30 | NCT03072927 | |
| A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-28 | NCT07144280 | |
| A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, cardiovascular disorder, chronic renal failure syndrome, hypertensive disorder, kidney disorder, kidney failure, urinary system disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06742723 | |
| Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery | Stage I Prostate Adenocarcinoma AJCC v7; Stage II Prostate Adenocarcinoma AJCC v7; Stage III Prostate Adenocarcinoma AJCC v7 | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-14 | NCT03070886 | |
| Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Inflammation, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, acute kidney injury, kidney cortex necrosis, kidney disorder, kidney failure, urinary system disorder | Recruiting | Not applicable | 2026-09-10 | NCT05758077 | |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-09 | NCT06966453 | |
| Breast Cancer WEight Loss Study (BWEL Study) | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast carcinoma in situ, breast disorder, breast neoplasm, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, invasive breast carcinoma, neoplasm, skin disorder, synchronous bilateral breast carcinoma | Active, not recruiting | Phase 3 | 2026-09-02 | NCT02750826 | |
| Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma | DS Stage I Multiple Myeloma; DS Stage II Multiple Myeloma; DS Stage III Multiple Myeloma | Active, not recruiting | Phase 3 | 2026-08-28 | NCT00098475 | |
| A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-07-23 | NCT06012435 | |
| A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, cardiovascular disorder, chronic renal failure syndrome, hypertensive disorder, kidney disorder, kidney failure, urinary system disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-06-26 | NCT06268873 | |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | acute coronary syndrome, cardiovascular disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Phase 3 | 2026-06-22 | NCT05918861 | |
| Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-05-06 | NCT02488967 | |
| Blood Purification for the Treatment of Pathogen Associated Shock | Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Shock, Systemic Inflammatory Response Syndrome, toxic shock syndrome | Active, not recruiting | Not applicable | 2026-04-14 | NCT05011656 | |
| Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast cancer, breast carcinoma in situ, breast disorder, breast neoplasm, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-03-05 | NCT01349322 | |
| RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck cancer, head and neck squamous cell carcinoma, mouth disorder, neoplasm, squamous cell carcinoma, tongue cancer, tongue disorder | Active, not recruiting | Phase 3 | 2026-01-06 | NCT00956007 | |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2025-08-20 | NCT03053193 | |
| Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2025-06-22 | NCT05607550 | |
| Verapamil for Neuroprotection in Stroke | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 1 / Phase 2 | 2025-01-17 | NCT03347786 | |
| Breast Cancer Index (BCI) Registry | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not stated | 2024-09-19 | NCT04875351 |